Executive Takeaway

The FDA approved 46 novel drugs in 2025, four fewer than 2024’s 50 approvals but still above the historic average of 36 new drugs per year since 1993. The five-year rolling average now sits at 48 approvals annually. Small molecules dominated at 65% (30 drugs), up from 56% in both 2023 and 2024. Oncology and hematology led therapeutic categories with 14 approvals, followed by rare disease indications.

Key highlights include Vertex’s first-in-class non-opioid painkiller Journavx, the first new antibiotic class for UTIs in nearly 30 years (Blujepa), and multiple precision oncology agents targeting specific mutations in lung cancer.

For 2026 planning, watch for continued dominance of precision oncology, accelerated pathways for rare diseases, and an emphasis on subcutaneous formulations that improve patient convenience.

What the FDA Means by “Novel Drug Approvals”

“Novel” drugs are new drugs never before approved or marketed in the U.S. The FDA’s Center for Drug Evaluation and Research (CDER) maintains the official list. This count specifically excludes vaccines, allergenic products, blood and blood products, plasma derivatives, and cellular and gene therapy products, which are approved separately by the Center for Biologics Evaluation and Research (CBER).

Some drugs are classified as New Molecular Entities (NMEs) for FDA review purposes, containing active moieties the FDA had not previously approved. However, FDA’s classification of a drug as an NME is distinct from its determination of whether a product is a “new chemical entity” under the Federal Food, Drug, and Cosmetic Act.

FDA Novel Drug Approvals 2025: Complete List

The table below presents all 46 novel drugs approved by CDER in 2025, including sponsor company, approval date, modality type, and therapeutic area. Source: FDA CDER Novel Drug Approvals list. This page will be updated if FDA edits the official list.

*Indications are abbreviated for presentation. See Drugs@FDA for full prescribing information.

2025 Approval Count and Context

At 46 novel drug approvals, 2025 represents a modest decline from recent peak years but remains historically strong. Context matters: 2024 saw 50 approvals, 2023 reached 55, while 2022 hit a decade low at 37. The five-year average now stands at 48 approvals per year, well above the 36-drug historic average since 1993.

The 2025 cohort was achieved despite significant regulatory turbulence, including leadership transitions, a 43-day government shutdown in October-November, and ongoing agency restructuring. Seven approvals came in December alone, with two cleared in the final week of the year (Yartemlea and Nereus).

Breakdowns That Matter Operationally

Approvals by Therapeutic Area

Oncology continued to dominate the approval landscape, accounting for nearly one-third of all approvals. Rare disease indications also featured prominently, reflecting the industry’s strategic pivot toward orphan drug designations and precision medicine.

Approvals by Modality

Small molecules reasserted dominance in 2025, comprising 65% of approvals (up from 56% in both 2023 and 2024). Monoclonal antibodies came in second at approximately 20%, with antibody-drug conjugates (ADCs), siRNA therapeutics, and bispecific antibodies representing emerging modality classes.

First-in-Class vs. Follow-On Dynamics

Notable first-in-class approvals in 2025 include:

• Journavx (suzetrigine) – First selective NaV1.8 inhibitor for acute pain and the first new non-opioid painkiller mechanism in over 20 years
• Blujepa (gepotidacin) – First new oral antibiotic class for UTIs in nearly 30 years
• Wayrilz (rilzabrutinib) – First BTK inhibitor approved for a non-oncology indication (immune thrombocytopenia)
• Multiple oncology approvals targeted specific genetic mutations previously lacking approved therapies, including EGFR exon 20 insertions and HER2-mutant lung cancers

The 5 Signals for 2026 That Leaders Should Actually Care About

1. Precision Oncology Fragmentation Continues: Five different NSCLC drugs approved in 2025 target distinct molecular subtypes (c-Met, ROS1, EGFR exon 20, HER2 mutations). Expect 2026 to bring even more granular biomarker stratification, requiring launch teams to build hyper-targeted commercial infrastructure.

2. Rare Disease Economics Strengthen: Orphan drug designations dominated 2025 approvals. With the FDA’s Rare Disease Evidence Principles (RDEP) framework now live, expect streamlined pathways for ultra-rare conditions. BD teams should prioritize assets with clear orphan drug strategy.

3. Subcutaneous Formulation Wave: Keytruda Qlex’s subcutaneous pembrolizumab approval signals a broader industry push to convert IV biologics to more convenient SC administration. Watch for reformulation programs to accelerate in 2026.

4. Hereditary Angioedema Crowding: Three HAE drugs approved in 2025 (Ekterly, Andembry, Dawnzera) across different mechanisms. This category exemplifies what happens when multiple sponsors chase the same validated rare disease market—competitive dynamics will intensify.

5. Infectious Disease Renaissance: Two novel antibiotics for gonorrhea (Nuzolvence, Blujepa extended indication) address rising antimicrobial resistance. Combined with RSV prevention (Enflonsia), expect renewed payer and policy attention to anti-infective development economics.

How to Use This Page

For BD/Licensing Screening: Filter by therapeutic area to identify active acquirers and their strategic focus. Note sponsor concentration patterns, particularly emerging players like Day One Biopharmaceuticals (two approvals) and Chinese-origin companies gaining U.S. traction.

For Competitive Planning: Use the modality breakdown to benchmark your pipeline composition against industry trends. The resurgence of small molecules suggests continued value in medicinal chemistry capabilities.

For Launch Benchmarking: Track approval timing patterns to calibrate your PDUFA date expectations. December’s seven approvals demonstrate FDA’s capacity for year-end surges.

Sources and Method

All entries sourced from the FDA CDER Novel Drug Approvals list. Therapeutic area and modality classifications applied by BioMed Nexus based on FDA-approved labeling. Sponsor information verified against Drugs@FDA approval letters.

For the FDA’s definition of “novel drug approvals” and scope exclusions, see: Novel Drug Approvals at FDA

Historical context and 5-year averages referenced from Nature Reviews Drug Discovery analysis (January 2026).

Frequently Asked Questions

What counts as a “novel drug” in the FDA list?
Novel drugs are new drugs never before approved or marketed in the U.S. They include new molecular entities (NMEs) and new therapeutic biologics reviewed by CDER.

Does this include vaccines or cell therapies?
No. The CDER novel drug list excludes vaccines, allergenic products, blood products, plasma derivatives, and cellular and gene therapy products. Those are approved by CBER and tracked separately.

How often does FDA update the list?
FDA typically updates the list within days of each approval, though timing can vary. During busy periods (like December), there may be brief lags. We recommend checking the FDA source page directly for the most current information.

Update Cadence: This page is checked weekly during January 2026, then monthly. Updates also triggered following major FDA Notable Approvals announcements.

Last updated: January 2026 | BioMed Nexus